Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy a randomized trial

Annals of Internal Medicine

Volumn 165, Issue 9, 2016, Pages 625-634

  Dore, Gregory J ^a   Altice, Frederick ^b   Litwin, Alain H ^c   Dalgard, Olav ^d   Gane, Edward J ^e   Shibolet, Oren ^f   Luetkemeyer, Anne ^g   Nahass, Ronald ^h   Peng, Cheng Yuan ⁱ   Conway, Brian ^j   Grebely, Jason ^a   Howe, Anita Y M ^k   Gendrano, Isaias N ^l   Chen, Erluo ^l   Huang, Hsueh Cheng ^l   Dutko, Frank J ^l   Nickle, David C ^l   Nguyen, Bach Yen ^l   Wahl, Janice ^l   Barr, Eliav ^l   Robertson, Michael N ^l   Platt, Heather L ^l   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e Auckland Clinical Studies   (New Zealand)

^f TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h ID Care   (United States)

ⁱ CHINA MEDICAL UNIVERSITY   (Taiwan)

^j VANCOUVER INFECTIOUS DISEASES CENTRE   (Canada)

^k ST PAUL S HOSPITAL   (Canada)

^l MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; ELBASVIR PLUS GRAZOPREVIR; METHADONE; OPIATE AGONIST; PLACEBO; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; DRUG COMBINATION; ELBASVIR-GRAZOPREVIR DRUG COMBINATION; IMIDAZOLE DERIVATIVE; QUINOXALINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUSTRALIA; CANADA; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; FRANCE; GERMANY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NETHERLANDS; NEW ZEALAND; NORWAY; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFECTION; SIDE EFFECT; SPAIN; TAIWAN; TREATMENT DURATION; UNITED KINGDOM; UNITED STATES; VIRUS RESISTANCE; ADOLESCENT; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; GENETICS; GENOTYPE; HEPATITIS C, CHRONIC; MEDICATION COMPLIANCE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RECURRENT DISEASE; SUBSTANCE ABUSE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BENZOFURANS; BUPRENORPHINE; BUPRENORPHINE, NALOXONE DRUG COMBINATION; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; QUINOXALINES; RECURRENCE; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84994388425     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-0816     Document Type: Article

References (27)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-62. [PMID: 23817321] doi:10.1038/nrgastro.2013.107
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128. [PMID: 23245604] doi:10.1016/S0140-6736(12)61728-0
3. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyn-iak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571-83. [PMID: 21802134] doi:10.1016/S0140-6736 (11)61097-0
4. Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol. 2015;63:364-9. [PMID: 25839406] doi:10.1016/j.jhep.2015.03.029
5. U.S. Food and Drug Administration. Prescribing information, ZEPATIER™ (elbasvir and grazoprevir) tablets, for oral use. January 2016. Accessed at www.accessdata.fda.gov/drugsatfda-docs/label/2016/208261Orig1s000lbl.pdf on 13 July 2016.
6. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56:4161-7. [PMID: 22615282] doi:10.1128/AAC.00324-12
7. Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013;8:1930-40. [PMID: 24127258] doi:10.1002/cmdc.201300343
8. Lahser F, Liu R, Bystol K, Xia E, Raubertas R, Asante-Appiah E, et al. A combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in vitro in HCV replicons. Hepatology. 2012;56(Suppl S1):236A.
9. Fraser I, Yeh WW, Reitmann C, Caro L, Talaty J, Guo Z, et al. Lack of PK interaction between the HCV protease inhibitor MK-5172 and methadone and buprenorphine/naloxone in subjects on stable opiate maintenance therapy [Poster]. Presented at 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cam-bridge, Massachusetts, 26-27 June 2013. Poster no. O-16.
10. Marshall WL, Marenco T, Feng HP, Barbour AM, Gilmartin J, Liu F, et al. No pharmacokinetic interaction between HCV NS5A inhibitor elbasvir and buprenorphine/naloxone in healthy volunteers. Hepatology. 2015;62(Suppl 1):573A.
11. Marshall WL, Caro L, Jumes P, Ma J, Mangin E, Liu Y, et al. Pharmacokinetic interaction between the HCV non-structural protein 5A inhibitor MK-8742 and methadone in subjects on stable mainte-nance therapy. Abstract no. 59. HepDART: Frontiers in Drug Devel-opment for Viral Hepatitis, 2013. Global Antiviral Journal. 2013; 9(Suppl 2):61.
12. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously un-treated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075-86. [PMID: 25467591] doi: 10.1016/S0140-6736(14)61795-5
13. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087-97. [PMID: 25467560] doi:10.1016/S0140-6736(14)61793-1
14. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319-27. [PMID: 26423374] doi:10.1016/S2352-3018(15)00114-9
15. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163:1-13. [PMID: 25909356] doi:10.7326/M15-0785
16. Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-13.
17. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-26. [PMID: 4023479]
18. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al; PHOTON-1 Investigators. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312:353-61. [PMID: 25038354] doi:10.1001/jama.2014.7734
19. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57 Suppl 2:S80-9. [PMID: 23884071] doi:10.1093/cid/cit306
20. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163:215-23. [PMID: 26120969] doi:10.7326/M15-0406
21. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, et al; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26: 1028-38. [PMID: 26282715] doi:10.1016/j.drugpo.2015.07.005
22. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199-236. [PMID: 25911336] doi:10.1016/j.jhep.2015.03.025
23. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. Recommendations for testing, manag-ing, and treating hepatitis C. AASLD guidelines. 2015. Accessed at www.hcvguidelines.org on 13 July 2016.
24. Grebely J, Bruggmann P, Backmund M, Dore GJ. Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57 Suppl 2:S29-31. [PMID: 23884062] doi:10.1093/cid/cit264
25. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55: 49-57. [PMID: 21898506] doi:10.1002/hep.24656
26. Martin B, Hennecke N, Lohmann V, Kayser A, Neumann-Haefelin C, Kukolj G, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol. 2014;61:538-43. [PMID: 24905492] doi:10.1016/j.jhep.2014.05.043
27. Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, Liang TJ, et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology. 2015;149:190-200. [PMID: 25754160] doi:10.1053/j.gastro.2015.03.004